Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to
the tumor.
PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who
have metastatic neuroendocrine tumors.